Sutro Biopharma Q3 2023: Revenue $16.9M, cash runway into H1 2025; luvelta data and new CSO

SUTRO BIOPHARMA, INC.

2023-Q3 EPS reported -$2.30 revenue$40,010,000

Cash and investments $321.1M plus Vaxcyte shares valued at $34.0M projecting runway into first half 2025.
Q3 2023 revenue $16.9M, down from $25.1M in Q3 2022; operating expenses $60.9M vs $46.4M.
Luvelta showed encouraging anti-tumor activity in FolRα-selected endometrial cancer at ESMO 2023; AML compassionate use data at ASH 2023.
Dr. Hans-Peter Gerber appointed Chief Scientific Officer in September 2023.
REFRaME-O1 Phase 2/3 trial for platinum-resistant ovarian cancer enrollment underway; global registration discussions with FDA/EMA.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.85

SUTRO BIOPHARMA, INC. reported financial results for the third quarter of 2023.

Period: the third quarter of 2023
Result: reported results

Exact text from the filing

On November 13, 2023, Sutro Biopharma, Inc. (the “ Company ”) issued a press release announcing its financial results for the quarter ended September 30, 2023.

View on SEC.gov

50 earnings releases filed in the last 30 days. Browse all earnings releases →

SUTRO BIOPHARMA, INC. filing history →

Source: SEC EDGAR

accession 0000950170-23-063021

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.